TY - JOUR
T1 - Efficacy of felodipine in stable effort angina - A double-blind, randomized and placebo-controlled trial
AU - Chen, C. Y.
AU - Jong, G. P.
AU - Chen, C. H.
AU - Chang, M. S.
PY - 1994
Y1 - 1994
N2 - A double-blind, randomized and placebo-controlled trial was carried out to evaluate the effectiveness of felodipine (F), a long-acting calcium blocker, in 29 male patients who had documented coronary artery disease (CAD) stable-effort angina, but no fresh infarction. Fourteen patients (pts) aged 65.5 ± 0.9 years taking placebos. The remaining 15 pts, aged 62.1 ± 0.9 years, were taking felodipine 10 mg once daily. All these pts were given placebo for the first four days, then divided to take placebo or felodipine. Each patient underwent maximal exercise testing to determine exercise duration, maximal oxygen consumption (MVO2) at 1st, 4th and 8th days, and 24-hour Holter's monitoring (Holter's ECG) was used to determine any episode of silent ischemia on the 4th and 8th days of the trial. Result: Age, resting blood pressure and heart rate, both exercise duration and (MVO2) of first and second MXT, total episodes of silent ischemia (ST depression > 1 mm, lasting longer than 1 minute) in the first Holter's electrocardiogram did not differ significantly between the felodipine and placebo patients. However, four day treatment with felodipine significantly (p < 0.05) prolonged the exercise duration (351.6 ± 47.1 vs 408.3 ± 44.5 seconds), delayed the onset of anaerobic metabolism (283 ± 30.8 vs 346 ± 32.7 seconds), decreased the amplitude of ST-segment depression (1.35 ± 0.29 vs 0.94 ± 0.27 mm) on exercising ECG and reduced the episodes of silent ischemia (4.8 ± 2.6 vs 3.4 ± 2.1) in the second Holter's ECG. However, after taking felodipine for four days, maximal double product decreased because maximal systolic blood pressure decreased (from 196.1 ± 9.9 down to 164.1 ± 5.2 mmHg, p < 0.01) without proportionally increased concomitantly in the maximal heart rate (from 146.5 ± 5.5 up to 151.0 ± 5.5 beat/min). A less increment of systolic blood pressure after maximal exercise post felodipine (31% vs 44%) indicated the vasodilatation effect of felodipine. It was concluded that felodipine 10 mg once daily, is an effective treatment for CAD patients with stable effort angina.
AB - A double-blind, randomized and placebo-controlled trial was carried out to evaluate the effectiveness of felodipine (F), a long-acting calcium blocker, in 29 male patients who had documented coronary artery disease (CAD) stable-effort angina, but no fresh infarction. Fourteen patients (pts) aged 65.5 ± 0.9 years taking placebos. The remaining 15 pts, aged 62.1 ± 0.9 years, were taking felodipine 10 mg once daily. All these pts were given placebo for the first four days, then divided to take placebo or felodipine. Each patient underwent maximal exercise testing to determine exercise duration, maximal oxygen consumption (MVO2) at 1st, 4th and 8th days, and 24-hour Holter's monitoring (Holter's ECG) was used to determine any episode of silent ischemia on the 4th and 8th days of the trial. Result: Age, resting blood pressure and heart rate, both exercise duration and (MVO2) of first and second MXT, total episodes of silent ischemia (ST depression > 1 mm, lasting longer than 1 minute) in the first Holter's electrocardiogram did not differ significantly between the felodipine and placebo patients. However, four day treatment with felodipine significantly (p < 0.05) prolonged the exercise duration (351.6 ± 47.1 vs 408.3 ± 44.5 seconds), delayed the onset of anaerobic metabolism (283 ± 30.8 vs 346 ± 32.7 seconds), decreased the amplitude of ST-segment depression (1.35 ± 0.29 vs 0.94 ± 0.27 mm) on exercising ECG and reduced the episodes of silent ischemia (4.8 ± 2.6 vs 3.4 ± 2.1) in the second Holter's ECG. However, after taking felodipine for four days, maximal double product decreased because maximal systolic blood pressure decreased (from 196.1 ± 9.9 down to 164.1 ± 5.2 mmHg, p < 0.01) without proportionally increased concomitantly in the maximal heart rate (from 146.5 ± 5.5 up to 151.0 ± 5.5 beat/min). A less increment of systolic blood pressure after maximal exercise post felodipine (31% vs 44%) indicated the vasodilatation effect of felodipine. It was concluded that felodipine 10 mg once daily, is an effective treatment for CAD patients with stable effort angina.
KW - felodipine
KW - maximal exercise testing
KW - stable angina
UR - http://www.scopus.com/inward/record.url?scp=0028213675&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0028213675
SN - 1011-6842
VL - 10
SP - 25
EP - 31
JO - Acta Cardiologica Sinica
JF - Acta Cardiologica Sinica
IS - 1
ER -